Singapore-based biotechnology company Mirxes is still considering listing itself on the Singapore Stock Exchange (SGX), after it filed for an IPO on the Hong Kong Exchanges and Clearing (HKEX) last week, according to a report by The Straits Times on Friday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
